Tipranavir (TPV, Aptivus) (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/daf/

Formulations

**Oral Solution:** 100 mg tipranavir/mL, with 116 International Units (IU) vitamin E/mL  
**Capsules:** 250 mg

<table>
<thead>
<tr>
<th>Dosing Recommendations</th>
<th>Selected Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note:</strong> Tipranavir must be boosted with ritonavir. The ritonavir boosting dose used for tipranavir is higher than the doses used for other protease inhibitors.</td>
<td>• Rare cases of fatal and non-fatal intracranial hemorrhage</td>
</tr>
</tbody>
</table>
| **Pediatric (Aged <2 Years) Dose:**  
  • Not approved for use in children aged <2 years | • Skin rash (more common in children than adults) |
| **Pediatric (Aged 2–18 Years) Dose:**  
  **Note:** Not recommended for treatment-naive patients | • Nausea, vomiting, diarrhea |
| **Body Surface Area Dosing:**  
  • Tipranavir/ritonavir (TPV/r) 375 mg/m²/150 mg/m², both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily) | • Hepatotoxicity: elevated transaminases; clinical hepatitis |
| **Weight-Based Dosing:**  
  • TPV/r 14 mg/kg/6 mg/kg, both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily) | • Hyperlipidemia |
| **Adult Dose:**  
  • TPV/r 500 mg (as two 250-mg capsules)/200 mg, both twice daily | • Hyperglycemia |
  • **Note:** Not recommended for treatment-naive patients | • Elevated creatine phosphokinase |

Special Instructions

• Administer tipranavir and ritonavir together and with food.
• Tipranavir oral solution contains 116 IU vitamin E per mL, which is significantly higher than the reference daily intake for vitamin E. Patients taking the oral solution should avoid taking any form of supplemental vitamin E that contains more vitamin E than found in a standard multivitamin.
• Tipranavir contains a sulfonamide moiety and should be used with caution in patients with sulfonamide allergy.
• Store tipranavir oral solution at room temperature, 25°C (77°F); do not refrigerate or freeze. Oral solution must be used within 60 days after the bottle is first opened.
• Store unopened bottles of oral tipranavir capsules in a refrigerator at 2°C to 8°C (36°F to 46°F). Once the bottle has been opened, capsules can be kept at room temperature (maximum of 77°F or 25°C) if used within 60 days.
• Use tipranavir with caution in patients who may be at increased risk of intracranial hemorrhage, including individuals with brain
Drug Interactions (see also the Adult and Adolescent Guidelines and HIV Drug Interaction Checker)

- Tipranavir has the potential for multiple drug interactions. Co-administration of tipranavir/ritonavir (TPV/r) with drugs that are highly dependent on cytochrome P (CYP) 3A for clearance or are potent CYP3A inducers is contraindicated.
- Before tipranavir is administered, a patient’s medication profile should be carefully reviewed for potential drug interactions.
- TPV/r is a potent enzyme inducer and has the potential to decrease plasma concentrations of other antiretroviral drugs. TPV/r significantly decreases plasma concentrations of etravirine. Etravirine and TPV/r should not be co-administered.
- TPV/r has been shown to decrease raltegravir concentrations. TPV/r dose adjustment is not currently recommended when raltegravir is administered twice daily. However, TPV/r should not be co-administered with raltegravir HD once daily because significantly lower raltegravir concentrations are likely to occur.
- Tipranavir should be used with caution in patients who are receiving medications known to increase the risk of bleeding, such as antiplatelet agents, anticoagulants, or high doses of supplemental vitamin E.

Major Toxicities

- More common: Diarrhea, nausea, fatigue, headache, rash (which is more frequent in children than in adults), and vomiting. Elevated transaminases, cholesterol, and triglycerides. Elevated creatine phosphokinase.
- Less common (more severe): Lipodystrophy. Hepatotoxicity: clinical hepatitis and hepatic decompensation, including some fatalities. Patients with chronic hepatitis B or hepatitis C coinfection or elevations in transaminases are at increased risk of developing further transaminase elevations or hepatic lesion, head trauma, recent neurosurgery, coagulopathy, hypertension, or alcoholism, or who use anticoagulant or antiplatelet agents (including vitamin E).
- Use of tipranavir is contraindicated in patients with moderate or severe hepatic impairment.

Metabolism/Elimination

- Cytochrome P450 3A4 (CYP3A4) inducer and substrate
- P-glycoprotein substrate

Tipranavir Dosing in Patients with Renal Impairment:
- No dose adjustment is required.

Tipranavir Dosing in Patients with Hepatic Impairment:
- No dose adjustment is required for mild hepatic impairment.
- Use of tipranavir is contraindicated in patients with moderate-to-severe hepatic impairment.
decompensation (approximately 2.5-fold risk). Epistaxis, which is more common with oral solution than capsule formulation.

- **Rare:** New-onset diabetes mellitus, hyperglycemia, ketoacidosis, exacerbation of preexisting diabetes mellitus, spontaneous bleeding in hemophiliacs. Increased risk of intracranial hemorrhage. Tipranavir should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other medical conditions.

**Resistance**

The International Antiviral Society-USA (IAS-USA) maintains a [list of updated resistance mutations](https://aidsinfo.nih.gov/guidelines) and the [Stanford University HIV Drug Resistance Database](https://aidsinfo.nih.gov/guidelines) offers a discussion of each mutation.

**Pediatric Use**

**Approval and General Considerations**

Tipranavir is approved for use in children aged as young as 2 years and is available in a liquid formulation. Its indication is limited to those patients who are treatment-experienced and who have HIV strains that are resistant to more than one protease inhibitor (PI). Tipranavir imposes a high pill burden on patients taking tipranavir capsules and requires a higher dose of boosting ritonavir than the doses used with other PIs. This increased dose of ritonavir is associated with a greater potential for drug interactions and increased toxicity. In addition, tipranavir is associated with serious adverse events (AEs) that limit its use to patients with few treatment options.

**Efficacy**

The Food and Drug Administration’s approval of tipranavir was based on a multicenter, pediatric study of the safety, efficacy, and pharmacokinetics (PKs) of TPV/r in children with HIV (PACTG 1051/BI-1182.14). This study enrolled 110 treatment-experienced children (with the exception of three treatment-naïve patients) aged 2 years to 18 years (with a median age of 11.7 years). Patients were randomized to receive two different dosing regimens. The higher dose of TPV/r (375 mg/150 mg/m² body surface area [BSA] twice daily) plus optimized background therapy was associated with better virologic responses at 48 weeks, particularly in the older, more heavily pretreated patients, when compared to the lower dose that was studied. A follow-up study of PACTG 1051 participants evaluated the long-term safety, efficacy, and tolerability of TPV/r in pediatric patients. At Week 288, most children were no longer receiving TPV/r. Reasons for discontinuation included AEs, virologic failure, and nonadherence. The youngest patients who were stable at Week 48 were more likely to still be on treatment after 5 years with continued efficacy.

**Pharmacokinetics**

PK evaluation of the liquid formulation at steady state in children was assessed. In children aged 2 to <12 years, a dose of TPV/r 290 mg/115 mg/m² BSA achieved tipranavir trough concentrations that were consistent with those achieved in adults receiving standard TPV/r 500 mg/200 mg dosing. However, children aged 12 to 18 years required a higher dose (375 mg/150 mg/m² BSA, 30% higher than the directly scaled adult dose) to achieve drug exposure similar to that seen in adults receiving the standard TPV/r dose. Based on available data, a dose of TPV/r 375 mg/150 mg/m² BSA twice daily is recommended.

**Toxicity**

AEs were similar between treatment groups in the multicenter, pediatric study. Twenty-five percent of children experienced a drug-related serious AE, and 9% of patients discontinued study drugs because of AEs. The most common AEs were gastrointestinal disturbances: 37% of participants had vomiting and 24% had diarrhea. The most common Grade 3 through 4 laboratory abnormalities were increases in the levels of creatine phosphokinase (11% of participants), alanine aminotransferase (6.5% of participants), and amylase (7.5% of participants). In the long-term follow-up report for PACTG 1051, incidence of AEs defined as drug-related was 55% to 65% regardless of age at entry, with higher discontinuation rates due to AEs in the older age groups.
Vitamin E is an excipient in the tipranavir oral solution, with a concentration of 116 international units (IU) of vitamin E and 100 mg tipranavir per mL of solution. The recommended dose of tipranavir (14 mg/kg body weight) results in a vitamin E dose of 16 IU/kg body weight per day, significantly higher than the reference daily intake for vitamin E (which is 30 IU for adults and approximately 6–22 IU for children and adolescents, depending on age of the child or adolescent) and close to the upper limit of tolerability for children. In PACTG 1051, bleeding events were reported more commonly in children receiving tipranavir oral capsules (14.3%) than in children taking tipranavir oral solution (5.75%). Overall, the incidence of bleeding episodes (primarily epistaxis) in pediatric patients observed in clinical trials was 7.5%.

References